

# Major shareholder announcement

With reference to company announcements dated 20 March 2023 related to the publication of a prospectus for its initial public offering and listing of the shares of Gubra A/S, CVR no. 30514041 (the "Company" or "Gubra") on Nasdaq Copenhagen, the prospectus as published by the Company and dated 30 March 2023 related to the result of the Offering, the Company today announces receipt of the following notifications pursuant to section 38 of the Danish Capital Markets Act regarding Arbejdsmarkedets Tillægspension's holding of shares in the Company.

#### **ATP**

Arbejdsmarkedets Tillægspension ("ATP") has subscribed for 1,363,636 shares in the Company, each with a nominal value of DKK 1, as part of the Offering. Following the completion and settlement of the Offering, ATP owns a total of 1,363,636 shares in the Company, each with a nominal value of DKK 1, corresponding to 8.34% of the share capital and voting rights.

#### Contacts

Media: Sofia Pitt Boserup, <a href="mailto:sbo@gubra.dk">sbo@gubra.dk</a>, +45 4188 9586 Investors: Kristian Borbos, <a href="mailto:kbo@gubra.dk">kbo@gubra.dk</a>, +45 3080 8035

## **About Us**

Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

This information is information which Gubra is obliged to make public pursuant to the Danish Capital Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-03-30 09:05 CEST.

### **Attachments**

Major shareholder announcement